On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of drugs for schizophrenia in more than 30 years.
In the hypothetical scenario where stance against performance-enhancing drugs (PEDs) is abolished, the strategic use of different substances would vary signific ...